Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects

Inclusion Criteria: * Male between 18 and 55 years of age inclusive. * AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN * Healthy as determined by a responsible and experienced physician. * Male subjects must agree to use one of the contraception methods requested. * Body weight greater than or equal to 50 kg, BMI ≤29.9kg/m2 * Capable of giving written informed consent. * QTcB or QTcF \< 450 msec. Exclusion Criteria: * A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result. * Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). * A positive pre-study drug/alcohol screen. * A positive test for HIV antibody. * Heart block, bundle branch block, hemi-block, evidence of accessory cardiac conduction pathways, long pauses \>2 s or other cardiac conduction abnormalities or cardiac arrhythmias on 12-lead ECG or 24 h Holter at screening. * History of regular excessive alcohol consumption within 6 months of the study. * The subject has participated in a clinical trial and has received an investigational product within 90 days o fthe strat of this study. * Exposure to more than four new chemical entities within 12 months prior to the first dosing day. * Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication. * History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. * Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. * Unwillingness or inability to follow the procedures outlined in the protocol. * Subject is mentally or legally incapacitated. * Subjects with a history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening. * Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication. * Average daily caffeine intake equivalent to \> 4 cups of coffee or \> 6 cups of tea. * Current or past history of symptomatic orthostatic hypotension or history of vasovagal episode(s). * Subjects with systolic blood pressure persistently above 140 mmHg and/or diastolic blood pressure persistently above 90 mmHg. * History of known or suspected seizures, including infantile febrile, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits). * The subject has a history of chronic pain before screening. * The subject has used any topical steroid in the previous 30 days if, in the opinion of the investigator this is likely to interfere with study assessments. * The subject has used any topical capsaicin preparations on the forearms in the previous 30 days. * The subject suffers from eczema, psoriasis or any other acute or chronic dermatological problem if, in the opinion of the investigator this is likely to interfere with study assessments * The subject suffers from tinnitus, or has done in the past 3 months. * Suffers from skin infection or inflammation of the forearm, or has other arm skin irregularities that may in the opinion of the investigator interfere with study assessments. * Needle phobic. * The subject does not produce an area of allodynia or hyperalgesia to the electrical hyperalgesia model during the screening session. * The subject is unable to tolerate the electrical hyperalgesia model or threshold tracking, including anxiety or atypical response to the stimulation. * Any history of suicidal behaviour or any suicidal ideation of type 4 or 5 on the C-SSRS in the last month. * Poor veins that would be estimated not to be suitable by a physician for repeated cannulation in both arms.